Mohammed, T., Ahmed, B. (2023). The Immunohistochemical Expression of PDL-1 in Prostate Carcinoma and Benign Prostatic Hyperplasia/ Clinico-Pathological Study. Alustath, 22(1), 16-20. doi: 10.52573/ipmj.2023.179185
Tamarah Kadhim Mohammed; Basim Shihab Ahmed. "The Immunohistochemical Expression of PDL-1 in Prostate Carcinoma and Benign Prostatic Hyperplasia/ Clinico-Pathological Study". Alustath, 22, 1, 2023, 16-20. doi: 10.52573/ipmj.2023.179185
Mohammed, T., Ahmed, B. (2023). 'The Immunohistochemical Expression of PDL-1 in Prostate Carcinoma and Benign Prostatic Hyperplasia/ Clinico-Pathological Study', Alustath, 22(1), pp. 16-20. doi: 10.52573/ipmj.2023.179185
Mohammed, T., Ahmed, B. The Immunohistochemical Expression of PDL-1 in Prostate Carcinoma and Benign Prostatic Hyperplasia/ Clinico-Pathological Study. Alustath, 2023; 22(1): 16-20. doi: 10.52573/ipmj.2023.179185

The Immunohistochemical Expression of PDL-1 in Prostate Carcinoma and Benign Prostatic Hyperplasia/ Clinico-Pathological Study

Iraqi Postgraduate Medical Journal
Article 4, Volume 22, Issue 1, January 2023, Pages 16-20    PDF (4.69 M)
DOI: 10.52573/ipmj.2023.179185
Authors
Tamarah Kadhim Mohammed1; Basim Shihab Ahmed2
1Al-Kindy Collage of Medicine, University of Baghdad, Baghdad, Iraq
2Ibn Sina University for Medical and Pharmaceutical Sciences, Baghdad, Iraq
Abstract
BACKGROUND:
Programmed death ligand 1 is tumor marker which is anti apoptotic factor (PD-L1, B7-H1, and CD274) and is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses.
THE AIMS OF STUDY :
To investigate the expression of Programmed death ligand 1 (PD-L1, B7-H1, CD274) in prostate cancer, benign prostatic hyperplasia, and normal prostatic tissue using anti-PD-L1 antibody; and to correlate the result of study with some clinico-pathological parameters such as the age of                       the patients and grade of tumor.
PATIENTS AND METHODS:
A retrospective case control study, included 90 cases was divided into three groups include 30 cases of Prostate cancer; 30 cases of benign prostate hyperplasia and 30 cases of normal prostatic tissue.
RESULTS:
Programmed death ligand 1was expressed in 10% of Prostate cancer cases and there is no expression in benign Prostatic hyperplasia and normal prostatic tissue. In Programmed death ligand1positive cases there is a significant correlation with age of patients, high Gleason score.
CONCLUSION:
Immunohistochemically, it is concluded that the expression of Programmed death ligand                           1 increases as the age of the patient increases, high Gleason score and there is no expression of Programmed death ligand 1in benign prostate hyperplasia and normal control tissue.
 
Keywords
PC: prostate cancer; PD-L1: programmed cell death-1ligand
References
  1. Zhang X; Zhang Q; Zhang Z; Na Y and Guo Y: Apoptosis profiles in benign prostatic hyperplasia: close associations of cell kinetics with percent area density of histologic composition. Urology 2006; 68: 905.
  2. Lawson RK: Role of growth factors in benign prostatic hyperplasia. Eur Urol 1997;32: 22.
  3. Berry SJ; Coffey DS, Walsh PC and Ewing LL: The development of human benign prostatic hyperplasia with age. J. Urol 1984; 132: 474.
  4. Chen J; Jiang CC; Jin L; Zhang XD. Regulation of PD-L1: a novel role of pro-survival signaling in cancer. Ann Oncol., 2015; 27:409–16. doi: 10.1093/annonc/mdv615.
  5. Dong, H. et al. (1999) Med. 5, 1365-9.
  6. Freeman, G.J. et al. (2000) Exp. Med., 192: 1027-1034.
  7. Liang; S.C. et al. (2003) J. Immunol. 33, 2706-16 1.
  8. Lyford-Pike S; Peng S; Young GD; Taube JM; Westra WH; Akpeng B, et al. Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013; 73:1733-41.
  9. Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, Majores M, Stein J, Uhl B, Muller S, Ellinger J, Stephan C, Jung K, et al. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clin Cancer Res., 2016; 22:1969–77.
  10. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med2015;373:123–35.
  11. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med2015; 373:1627–39.
  12. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet2016; 387:1540–50.
  13. Garon EB, Rizvi NA, Hui R. KEYNOTE-001 investigators: pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med2015;372:2018–28.
  14. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature2014; 515:563–67.
  15. Rumsey J, statistics for Dummies, 2nd addition, 2016.
  16. Surveillance, Epidemiology, and End Results Program (SEER) of the National Cancer Institute. Fast Stats: An interactive tool for access to SEER cancer statistics.Bethesda, MD: SEER, National Cancer Institute; nd. (Accessed November 11, 2011). 
  17. Christian D. Fankhauser, Peter J. Schüffler, Silke Gillessen, Aurelius Omlin, Niels J. Rupp, Jan H. Rueschoff, Thomas Hermanns, Cedric Poyet, Tullio Sulser, Holger Moch and Peter J. Wild, Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer,oncotarget, November 15, 2017.
  18. Untergasser G, et al, Benign prostatic hyperplasia: age-related tissue-remodeling, Exp Gerontol, 2015.
  19. Curtis Nickel J., MD, Inflammation and benign prostatic hyperplasia, The Urologic clinics of North America, 2008.
 

Statistics
Article View: 33
PDF Download: 56


Journal Management System. Powered by ejournalplus.com